Shares of Organon & Co. (OGN) are actively acquired and held by a broad institutional base consisting of mutual funds, pension funds, global asset management firms, and quantitative value investors. Because the healthcare stock screens attractively on certain fundamental valuation metrics and offers defensive healthcare exposure, value-seeking institutional managers alongside retail market participants comprise the primary buyers on public exchanges.